LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Xaar Plc

-2.00 (-1.14%)
Share Name Share Symbol Market Type Share ISIN Share Description
Xaar Plc LSE:XAR London Ordinary Share GB0001570810 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.00 -1.14% 174.00 96,046 16:35:05
Bid Price Offer Price High Price Low Price Open Price
170.50 173.50 173.50 173.50 173.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Printing Diversified 72.78 1.63 2.10 88.00 136.34
Last Trade Time Trade Type Trade Size Trade Price Currency
16:37:29 O 25,000 173.50 GBX

Xaar (XAR) Latest News

Xaar (XAR) Discussions and Chat

Xaar Forums and Chat

Date Time Title Posts
02/5/202311:22XAAR - 2006 & Beyond4,908
17/12/201415:44Tip TV Daily market Round-up-
28/8/201414:44XAAR 2004 - MAJOR RECOVERY IN PROGRESS1,081

Add a New Thread

Xaar (XAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Xaar (XAR) Top Chat Posts

Top Posts
Posted at 20/4/2023 11:39 by simmsc
opinions appear to be really split on this stock. possibly as it has some growth elements in there and it also has some recovery elements to it - which make it a bit of a hybrid stock. I share napoleons view that this will go ballistic at some stage as this will very much be a needed technology for those who want to stay in the game. Once their competitors integrate (or switch back to) Xaar's print technology, the others will have to switch. Purely just from a lead time prospective alone (let alone all the other benefits that come with it - cost, quality, efficiency, ESG credentials, etc). Sit tight and hold, possibly also buy on dips at these lower prices (if you dont have a full position in it yet).
Posted at 08/4/2023 22:00 by napoleon 14th
This share is primed to go balistic IMO. I bought in H3'20, now up 140%.

SCSW like them - 30p eps anticipated in 2025 = P/E of 6.66666.
If 30p eps, a P/E of 20 = 600p.

"Small Caps Live Weekly" were far more stingy. I usually enjoy their "acid test"
analysis but IMO they got this one wrong.
They say "The EPS consensus of 3.02p does look achievable given the acquisitions, but this is a forward P/E of 60 and a PEG of over 2. This is still below 2021 EPS tho, so should this really be on a growth rating? Something like 10x forward earnings, or around 30p, would seem to be fair value here, given the very patchy track record."
but nowt about successful reorg. & sales prospects.
I bought on a 5 year view... Should easially double from here.

Posted at 13/3/2023 14:22 by gargoyle2
Tipped in SCSW at the weekend -- 'I think XAR is set to become a big BUY in the latter part of the year but looking at its history, it could easily surprise positively sooner.'
Posted at 25/1/2023 13:03 by napoleon 14th
Up 100%+ after 2.5 years in XAR, but greed and realism tell me to keep until £5.
Posted at 12/1/2023 16:52 by dr biotech
Simon Thompson of the IC calls it a sell.

...cost inflation (labour and energy) is having an impact, too, prompting analysts at Progressive Equity to downgrade their 2023 pre-tax profit and earnings per share (EPS) forecasts by 44 per cent to £2.5mn and 3.2p, respectively, on revenue of £79.6mn (3 per cent downgrade)... group net cash fell by a third to £8.6mn in the second half of 2022, although analysts expect it to recover to £11.3mn by the end of 2023.

Although management is making the right strategic moves...there is no avoiding the short-term headwinds, nor the scale of the earnings downgrade. Bank the 388 per cent paper profit. Sell.

Posted at 20/9/2022 09:20 by brucie5
No comment? These look pretty good to me.

Summary of results for the six months ended 30 June 2022:

2022 2021(1) Change
Continuing Operations
---------- ---------- ------
Revenue GBP36.6m GBP26.3m +39%
---------- ---------- ------
Gross profit GBP14.5m GBP8.3m +75%
---------- ---------- ------
Gross margin % 40% 31% +9ppts
---------- ---------- ------
Gross R&D investment GBP3.3m GBP2.6m +27%
---------- ---------- ------
Adjusted EBITDA(2) GBP3.0m GBP0.3m
---------- ---------- ------
Adjusted profit/(loss) GBP1.4m (GBP1.6m)
before tax(2)
---------- ---------- ------
Loss before tax (GBP0.3m) (GBP1.4m)
---------- ---------- ------
Profit/(loss) for the GBP0.7m (GBP1.3m)
period after tax
---------- ---------- ------
Basic earnings per share 0.9p (1.6p)
---------- ---------- ------

Total Operations
---------- ---------- ------
Loss before tax (GBP0.6m) (GBP4.2m) +85%
---------- ---------- ------
Profit/(loss) for the
period after tax GBP0.4m (GBP4.3m) +108%
---------- ---------- ------
Basic earnings per share 0.5p (3.8p) +112%
---------- ---------- ------

Net cash at the period
end(3) GBP12.7m GBP17.1m -26%
---------- ---------- ------

Posted at 24/7/2022 13:23 by brucie5
Well, yes and no. A stonkingly high PE can also be evidence of an overvalued share price.
It really depends on growth in those earnings, hence Slater's interest in PEG ratio. But the case for XAR, I believe, having listened to CR, is its reinvention on basis of its IP larder, and potential demand for its new aquieous ink product, with enhanced ESG.

Posted at 15/7/2022 09:44 by se81
and more commentary from Progressive today after the update yesterday (Paid for "research" of course but a good way for the co to communicate with investors outside scheduled updates)

Xaar’s H1 trading update for 6M ended 30th June 2022, issued yesterday, confirms that the group is trading well, with increased revenues, improving margins, costs under control and new products launching to schedule. Xaar is clearly back onto a robust growth trajectory. We are maintaining our forecasts and look forward to the interims in September as an opportunity find out more about how the momentum is building.
▪ Revenues and profits growth in line with expectations - The statement confirms that after a strong H1, performance for the full year at PBT level is seen as being in line with expectations. Revenues for H1 are expected to be approx. £37m – 41% up YoY and 14% up on an organic basis before the FFEI and Megnajet. The strong revenue growth has been accompanied by increased gross margins and effective actions on costs.
▪ Investment continues – Net Cash as at 30th June was £12.6m, down from the year end figure of £15.3m. This is consistent with our forecasts, given the acquisition of Megnajet, the ongoing capital investments and the requirement to increase working capital to protect Xaar from supply chain issues and to ensure that customers’ requirements are met.
▪ Trading encouraging on all fronts - The core printhead division has traded well, with European and US growth offsetting the Covid related slowdown in China. The product print business, eps, has seen both revenue and margin growth.
▪ Product development going to plan - The statement confirms that not only has trading performance been good, but so has progress with new product development. A new printbar product was launched in H1 by FFEI, but most importantly the company remains on track to launch the much-anticipated aqueous printhead product in Q4 2022.
▪Price increases, not just cost cutting - The statement refers to management actions to mitigate the impact of cost increases – not least of which is the fact that Xaar has successfully put through sales price increases. This is a timely and reassuring reminder that it has products, skills and technologies that customers value and are willing to pay up for.
Xaar offers investors a clear, understandable tech growth story with a near $1bn addressable market opportunity and a management team that is demonstrating its ability to execute. We continue to question whether the value of this combination is fully reflected in the share price.

Posted at 22/6/2022 07:43 by se81
Progressive out with a new (free) note this morning....some interesting stuff in there (re the business, products, future growth etc)- headline summary below

With a clear roadmap of new digital inkjet products and an ambitious
management team focused on gaining (or retaining) significant market
shares across the segments that make up its $1bn addressable market, Xaar
is positioned to grow strongly. Management has already demonstrated its
abilities in turning the business around, and we believe it is far from clear
that the share price fully reflects the opportunities ahead.

▪ $1bn market awaits. The market for industrial digital inkjet printheads is
estimated by management to be approaching $1bn per annum. Xaar’s
product roadmap suggests that it will be able to address the vast majority
of this within a few years. If the management team delivers on the
product roadmap, Xaar will be well-positioned to take a strong share of
these markets.

▪ Clear signs of progress. Management has a strategy in place to drive
revenue back up by launching new products and adopting a revised
approach to customers and the channel. Improving revenues and a
growing number of customer products both in development and in the
market show that management is already delivering on this strategy.

▪ Profit and cashflow upside. The high gross margin and relatively fixed cost
base mean that as product and revenue traction build, the impact on the
bottom line will be geared upwards. On top of this, the significant
historical capital investment means that material increases in output can
be achieved for limited capital outlay: a possible positive profit and
cashflow double whammy.

▪ ESG potential. Management believes that Xaar can reduce overall ink and
energy consumption, most notably with the launch of its aqueous ink
capable printheads, which use significantly less water than standard
printheads and save on the heat energy used to dry the inks.
Starting from £40m revenue in printheads in FY21, a near $1bn addressable
market opportunity and a management team that has shown itself able to
execute, even though the shares are on premium multiples, the market
valuation appears that it may not fully reflect the scale of Xaar’s potential
revenue and profit growth. Xaar offers investors a clear, understandable
technology growth story, building on an established set of technologies
providing solutions across a range of demanding printing applications.

Posted at 28/4/2022 10:05 by tomps2
XAR pitched in the latest episode of Sell It To The City

Richard Crow pitches Xaar (XAR) to leading fund managers, Andy Brough, Judith MacKenzie and Stephen English at 2m20s in the latest PIWORLD Sell It To The city.

Watch the video here:

Or listen to the podcast here:

Xaar share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 21:08:04